Posting: # 20530
Today I have to read this here:
But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...
Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?
Kindest regards, nobody